BPMC vs. ONC, BNTX, TEVA, INSM, SMMT, ITCI, GMAB, RDY, QGEN, and MRNA
Should you be buying Blueprint Medicines stock or one of its competitors? The main competitors of Blueprint Medicines include BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Insmed (INSM), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.
Blueprint Medicines vs. Its Competitors
BeOne Medicines (NASDAQ:ONC) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.
BeOne Medicines has a net margin of -9.40% compared to Blueprint Medicines' net margin of -27.70%. BeOne Medicines' return on equity of -7.55% beat Blueprint Medicines' return on equity.
BeOne Medicines has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.
In the previous week, Blueprint Medicines had 4 more articles in the media than BeOne Medicines. MarketBeat recorded 5 mentions for Blueprint Medicines and 1 mentions for BeOne Medicines. Blueprint Medicines' average media sentiment score of 0.81 beat BeOne Medicines' score of 0.00 indicating that Blueprint Medicines is being referred to more favorably in the news media.
Blueprint Medicines has lower revenue, but higher earnings than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than Blueprint Medicines, indicating that it is currently the more affordable of the two stocks.
BeOne Medicines currently has a consensus target price of $320.67, suggesting a potential upside of 30.62%. Blueprint Medicines has a consensus target price of $128.06, suggesting a potential downside of 0.16%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts plainly believe BeOne Medicines is more favorable than Blueprint Medicines.
48.6% of BeOne Medicines shares are held by institutional investors. 6.6% of BeOne Medicines shares are held by company insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
BeOne Medicines beats Blueprint Medicines on 9 of the 17 factors compared between the two stocks.
Get Blueprint Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BPMC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Blueprint Medicines Competitors List
Related Companies and Tools
This page (NASDAQ:BPMC) was last updated on 7/7/2025 by MarketBeat.com Staff
